Keryx Biopharmaceuticals to Hold Conference Call Tomorrow at 8:00 AM ET to Discuss Top-Line Results from Zerenex™ Phase 3 Long

  Keryx Biopharmaceuticals to Hold Conference Call Tomorrow at 8:00 AM ET to
        Discuss Top-Line Results from Zerenex™ Phase 3 Long-Term Study

PR Newswire

NEW YORK, Jan. 27, 2013

NEW YORK, Jan. 27, 2013 /PRNewswire/ --Keryx Biopharmaceuticals, Inc.
(NASDAQ: KERX) will host a conference call tomorrow, Monday, January 28, at
8:00am ET to review the top-line results from the Phase 3 long-term study
component of its Phase 3 registration program of Zerenex^™ (ferric citrate),
the Company's ferric iron-based phosphate binder for the treatment of elevated
serum phosphorus levels, or hyperphosphatemia, in patients with end-stage
renal disease on dialysis. Keryx will announce the top-line results tomorrow
morning, prior to the call.

Ron Bentsur, Chief Executive Officer of Keryx, will host the call. Dr. Julia
Lewis, Professor of Medicine, Department of Nephrology, Vanderbilt University
School of Medicine, and member of the Executive Committee of the Collaborative
Study Group, and Study Chair of the Zerenex Phase 3 registration program, will
also join the call.

In order to participate in the conference call, please call 1-877-869-3847
(U.S.), 1-201-689-8261 (outside the U.S.), call-in ID: KERYX. The rebroadcast
of the conference call will be available for replay at http://www.keryx.com,
for a period of 15 days after the call.

About Keryx Biopharmaceuticals, Inc.
Keryx Biopharmaceuticalsis focused on the acquisition, development and
commercialization of medically important pharmaceutical products for the
treatment of renal disease. Keryx is developing Zerenex (ferric citrate), an
oral, ferric iron-based compound that has the capacity to bind to phosphate
and form non-absorbable complexes. The U.S.-based Phase 3 clinical program of
Zerenex for the treatment of hyperphosphatemia (elevated phosphate levels) in
patients with end-stage renal disease is being conducted pursuant to a Special
Protocol Assessment (SPA) agreement with the FDA. Zerenex is also in Phase 2
development for the management of phosphorus and iron deficiency in anemic
patients with Stage 3 to 5 non-dialysis dependent chronic kidney disease. In
addition, Keryx's Japanese partner, Japan Tobacco Inc. and Torii
Pharmaceutical Co., Ltd. has filed its New Drug Application for marketing
approval of ferric citrate in Japan for the treatment of hyperphosphatemia in
patients with chronic kidney disease. Keryx is headquartered in New York
City.

KERYX CONTACT:
Lauren Fischer
Director - Investor Relations
Keryx Biopharmaceuticals, Inc.
Tel: 212.531.5965
E-mail: lfischer@keryx.com

SOURCE Keryx Biopharmaceuticals, Inc.

Website: http://www.keryx.com
 
Press spacebar to pause and continue. Press esc to stop.